1. Home
  2. CBU vs BLLN Comparison

CBU vs BLLN Comparison

Compare CBU & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBU

Community Bank System Inc.

HOLD

Current Price

$62.03

Market Cap

3.5B

Sector

Finance

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$73.45

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBU
BLLN
Founded
1866
2016
Country
United States
United States
Employees
N/A
713
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
CBU
BLLN
Price
$62.03
$73.45
Analyst Decision
Hold
Buy
Analyst Count
4
7
Target Price
$66.67
$126.71
AVG Volume (30 Days)
172.0K
380.2K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
2.98%
N/A
EPS Growth
15.41
N/A
EPS
3.97
N/A
Revenue
$818,007,000.00
N/A
Revenue This Year
$13.46
$46.29
Revenue Next Year
$7.75
$30.14
P/E Ratio
$15.96
N/A
Revenue Growth
9.61
N/A
52 Week Low
$51.12
$61.96
52 Week High
$67.50
$138.70

Technical Indicators

Market Signals
Indicator
CBU
BLLN
Relative Strength Index (RSI) 54.55 41.26
Support Level $60.17 $64.99
Resistance Level $64.73 $83.20
Average True Range (ATR) 1.28 6.48
MACD 0.01 -1.05
Stochastic Oscillator 42.03 9.57

Price Performance

Historical Comparison
CBU
BLLN

About CBU Community Bank System Inc.

Community Financial System Inc is a diversified financial services company providing a broad array of banking and other financial services to retail, commercial, institutional and governmental customers. The Company also offers comprehensive financial planning, trust administration and wealth management services through its Community Bank Wealth Management operating unit. It has four reportable operating business segments: Banking and Corporate, Employee Benefit Services, Insurance Services and Wealth Management Services.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: